First-line afatinib for the treatment of EGFR mutation-positive non-small-cell lung cancer in the 'real-world' clinical setting
10.1177/1758835919836374
Saved in:
Main Authors: | , , , |
---|---|
Other Authors: | |
Format: | Review |
Language: | English |
Published: |
SAGE PUBLICATIONS LTD
2022
|
Subjects: | |
Online Access: | https://scholarbank.nus.edu.sg/handle/10635/218616 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | National University of Singapore |
Language: | English |
id |
sg-nus-scholar.10635-218616 |
---|---|
record_format |
dspace |
spelling |
sg-nus-scholar.10635-2186162023-10-31T20:32:39Z First-line afatinib for the treatment of EGFR mutation-positive non-small-cell lung cancer in the 'real-world' clinical setting Park, Keunchil Lim, Darren Wan-Teck Okamoto, Isamu Yang, James Chih-Hsin DUKE-NUS MEDICAL SCHOOL Science & Technology Life Sciences & Biomedicine Oncology afatinib brain metastases EGFR tyrosine kinase inhibitors NSCLC real-world uncommon mutations OPEN-LABEL BRAIN METASTASES NAIVE PATIENTS ACQUIRED-RESISTANCE PLUS NSCLC PHASE-III GEFITINIB ADENOCARCINOMA ERLOTINIB CHEMOTHERAPY 10.1177/1758835919836374 THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY 11 2022-04-07T08:32:48Z 2022-04-07T08:32:48Z 2019-04-01 2022-04-07T02:39:05Z Review Park, Keunchil, Lim, Darren Wan-Teck, Okamoto, Isamu, Yang, James Chih-Hsin (2019-04-01). First-line afatinib for the treatment of EGFR mutation-positive non-small-cell lung cancer in the 'real-world' clinical setting. THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY 11. ScholarBank@NUS Repository. https://doi.org/10.1177/1758835919836374 17588340 17588359 https://scholarbank.nus.edu.sg/handle/10635/218616 en SAGE PUBLICATIONS LTD Elements |
institution |
National University of Singapore |
building |
NUS Library |
continent |
Asia |
country |
Singapore Singapore |
content_provider |
NUS Library |
collection |
ScholarBank@NUS |
language |
English |
topic |
Science & Technology Life Sciences & Biomedicine Oncology afatinib brain metastases EGFR tyrosine kinase inhibitors NSCLC real-world uncommon mutations OPEN-LABEL BRAIN METASTASES NAIVE PATIENTS ACQUIRED-RESISTANCE PLUS NSCLC PHASE-III GEFITINIB ADENOCARCINOMA ERLOTINIB CHEMOTHERAPY |
spellingShingle |
Science & Technology Life Sciences & Biomedicine Oncology afatinib brain metastases EGFR tyrosine kinase inhibitors NSCLC real-world uncommon mutations OPEN-LABEL BRAIN METASTASES NAIVE PATIENTS ACQUIRED-RESISTANCE PLUS NSCLC PHASE-III GEFITINIB ADENOCARCINOMA ERLOTINIB CHEMOTHERAPY Park, Keunchil Lim, Darren Wan-Teck Okamoto, Isamu Yang, James Chih-Hsin First-line afatinib for the treatment of EGFR mutation-positive non-small-cell lung cancer in the 'real-world' clinical setting |
description |
10.1177/1758835919836374 |
author2 |
DUKE-NUS MEDICAL SCHOOL |
author_facet |
DUKE-NUS MEDICAL SCHOOL Park, Keunchil Lim, Darren Wan-Teck Okamoto, Isamu Yang, James Chih-Hsin |
format |
Review |
author |
Park, Keunchil Lim, Darren Wan-Teck Okamoto, Isamu Yang, James Chih-Hsin |
author_sort |
Park, Keunchil |
title |
First-line afatinib for the treatment of EGFR mutation-positive non-small-cell lung cancer in the 'real-world' clinical setting |
title_short |
First-line afatinib for the treatment of EGFR mutation-positive non-small-cell lung cancer in the 'real-world' clinical setting |
title_full |
First-line afatinib for the treatment of EGFR mutation-positive non-small-cell lung cancer in the 'real-world' clinical setting |
title_fullStr |
First-line afatinib for the treatment of EGFR mutation-positive non-small-cell lung cancer in the 'real-world' clinical setting |
title_full_unstemmed |
First-line afatinib for the treatment of EGFR mutation-positive non-small-cell lung cancer in the 'real-world' clinical setting |
title_sort |
first-line afatinib for the treatment of egfr mutation-positive non-small-cell lung cancer in the 'real-world' clinical setting |
publisher |
SAGE PUBLICATIONS LTD |
publishDate |
2022 |
url |
https://scholarbank.nus.edu.sg/handle/10635/218616 |
_version_ |
1781793042274975744 |